Daiichi to buy Accumetrics?

Discussion in 'Daiichi-Sankyo' started by Anonymous, Jul 1, 2010 at 11:09 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Re: Daiichi to buy Accumetrics? - MORE FINANCING!

    Bingo!

    Another $7 million capital financing from the VCs...

    "The closure of this financing demonstrates continued and unwavering confidence from our investor base," said Timothy I. Still, President and CEO of Accumetrics. "We are excited to be positioned at the forefront of a major market shift in the healthcare sector where medical diagnostics will play a greater role in personalizing patient treatment."
     

  2. Anonymous

    Anonymous Guest

    Panic to bring in business at Accumetrics......The investors need to wake up to the Still/Chisolm scam. By the way, when are they releasing the machines that were used for the Lilly/Effient trial ....Hmmmmmmm//// Will Accumetrics tell their salespeople and other sales channels? I'm sick of the BS and lies.
     
  3. Anonymous

    Anonymous Guest

    Barely used machines are already hitting the market (450 that were used by DSI for the Effient trials) Accumetrics is turning their eyes, as Lilly has a financial stake in the sale of these machines. They were leased.
     
  4. Anonymous

    Anonymous Guest

    Sounds like another Glucowatch fiasco! Keep in mind that John G got us into that and he is going to be our next CEO! We are not better off than the Accumetrics people.
     
  5. Anonymous

    Anonymous Guest

    OMG! JG has a large vagina.
     
  6. Anonymous

    Anonymous Guest

  7. Anonymous

    Anonymous Guest

    It is absolutely a travesty how this company has blown this opportunity. Still and Chisolm are INCOMPETENT. Pilot program flop, Gravitas "need more research" waste of money, diluting sales channels and causing drastic drop in ASP, showing sales growth by increasing prices to dealers.....What a joke, good luck selling this company now.

    I agree with the previous post, whoever is putting money into this bomb hasn't done any real deep research lately.
     
  8. Anonymous

    Anonymous Guest

    450 machines available for sale with printers, with Accumetrics blessings. Bend over.
     
  9. Anonymous

    Anonymous Guest

    Accumetrics is in deep trouble

    Coming back from the AHA, my feeling is this company is in deep trouble:

    - the technology: no significant predictivity in both multicenter studies performed: IMO people underestimate that this is the really sad message of the GRAVITAS data, even worse than the lack of benefit in the high clopidogrel group. See slide 19 in: http://sciencenews.myamericanheart.org/pdfs/GRAVITAS_pslides.pdf
    And also slide 28 in:
    http://spo.escardio.org/eslides/view.aspx?eevtid=33&fp=4989
    Failure to show any significant predictivity in two multi-center studies with 1001 patients (Verifrenchy) and 1691 patients (Gravitas observational substudy) means that the technology is not able to do what it is supposed to do: to identify patients at significantly increased risk.

    - the management: The accumetrics management seems to suffer from an inverse Midas syndrome: everything they do seems to fail. Also you meet all the time people that have negative stories about them to tell (or posts in this and other forums), and nobody who seems to be positive about them - obviously except from the investors.

    - financial data: 05-2003: series A financing $1.3 million, 07-2004: series B financing $13.5 million, 02-2006: series C financing $8.25 million, 02-2008: series D financing $28.8 million, 10-2009: series E financing $16.6 million, additional $7 million announced in 9-2010.
    $75.5 million in VC???
    Is this a company or a Ponzi scheme?
    $52.4 million since 2008, which is approximatelly $1.5 million per MONTH.
    They don´t need a buyer, they need a bailout IMO. Perhaps Obama can help.
     
  10. Anonymous

    Anonymous Guest

  11. Anonymous

    Anonymous Guest

    Having the reverse Midas touch is a kind way of saying that everything these 2 touch turns to poo. Even that is an understatement. They can point to increasing sales, but what they fail to realize is that they could have increased earnings and sales exponentially from what they are. The salient issue most people in the company agree on is that management is tone deaf, if not completely deaf to any suggestions from anyone. They are inept. Look at the booth they had at the meetings, no one can stand 20 feet away and make a determination what the company is selling. Product is discounted severely in the market, since there is no definitive distribution channel, hell, most companies try to protect ASP by protecting territories. These idiots believe that if everyone is selling it, we will sell more. They got lucky in their last position due to competitive product recall, they looked like sales stars. Chisolm imho doesn't have an ounce of sales/marketing acumen. Literally an empty, brain dead, suit.
     
  12. Anonymous

    Anonymous Guest

    Name Change?

    What about verynotnowtest?
     
  13. Anonymous

    Anonymous Guest

    It seems that all VerifyNow has done is confuse doctors. The reps (with massive territories) seem to be uneducated/unaware of the data and how this technology can fit with genotyping. It seems that they have been selling this as a stand alone test...which is a miss...see GRAVITAS..and aren't responsive to lab managers/doctors when there is a run of non-responders.

    Looks like other people will be left to clean up the mess after this company tanks....
     
  14. Anonymous

    Anonymous Guest

    From the Accumetrics press release:

    “GRAVITAS continues to position Accumetrics as a diagnostic leader that invests in furthering clinical understanding of individualized treatment for cardiovascular patients,” said Timothy I. Still, President and CEO of Accumetrics.

    Does he want to tell us he is good in spending money??
     
  15. Anonymous

    Anonymous Guest

    The seem to be doing better, in spite of Gravitas. $18 million revenue in 2010 does not sound that bad. What do the cassandras in this forum say about that?
     
  16. Anonymous

    Anonymous Guest

    Classic! I think the engineer that developed the Glucowatch, moved over to develop Verify Now!
     
  17. Anonymous

    Anonymous Guest

    .. and CEO was captain on the Titanic!
     
  18. Anonymous

    Anonymous Guest

    Some of my key cardiologists have started calling it 'VERIFY NOT NOW'
     
  19. Anonymous

    Anonymous Guest

    New cash?

    When does Accumetrics need its next cash infusion? They received another $7 Mn in September. burning $1 Mn per month, this means they need the next financing round SOON.
     
  20. Anonymous

    Anonymous Guest

    I think nobody is interested in this company anymore since the GRAVITAS disaster..